Clinical trial
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
NCT00089791 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00089791 |
|---|---|
| Title | A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis |
| Official title | A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | placebo, Denosumab |
| Enrollment | 7,808 |
| Start date | Aug 1, 2004 |
| Primary completion | Jun 17, 2008 |
| Completion | Jun 17, 2008 |
| First posted | Aug 16, 2004 |
| Last update posted | Nov 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: